Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents
(Last updated:6/17/2013; last reviewed:5/7/2013)
Cryptosporidiosis is caused by various species of the protozoan parasite Cryptosporidium
, which infect the small bowel mucosa and, if symptomatic, typically cause diarrhea. Cryptosporidium
can also infect other gastrointestinal and extraintestinal sites, especially in individuals whose immune systems are suppressed. Advanced immunosuppression—typically CD4 T lymphocyte cell (CD4) counts of <100 cells/µL1
—is associated with the greatest risk for prolonged, severe, or extraintestinal cryptosporidiosis. The three species that most commonly infect humans are Cryptosporidium hominis
, Cryptosporidium parvum
, and Cryptosporidium meleagridis
. Infections are usually caused by one species, but a mixed infection is possible.2
Cryptosporidiosis remains a common cause of chronic diarrhea in AIDS patients in developing countries, with up to 74% of diarrheal stools demonstrating the organism.3
In developed countries with low rates of environmental contamination and where potent antiretroviral therapy (ART) is widely available, cryptosporidiosis has decreased and occurs at an incidence of <1 case per 1000 person-years in patients with AIDS.4
Infection occurs through ingestion of Cryptosporidium
oocysts. Viable oocysts in feces can be transmitted directly through contact with infected humans or animals, particularly those with diarrhea. Oocysts can contaminate recreational water sources such as swimming pools and lakes, and public water supplies and may persist despite standard chlorination (see Appendix: Food and Water-Related Exposures
). Person-to-person transmission is common, especially among sexually active men who have sex with men.
Patients with cryptosporidiosis most commonly have acute or subacute onset of watery diarrhea, which may be accompanied by nausea, vomiting, and lower abdominal cramping. Severity can range from asymptomatic to profuse, cholera-like diarrhea. More severe symptoms tend to occur in immune-suppressed patients, whereas transient diarrhea alone is typical in hosts with competent immune systems. Fever is present in approximately one-third of patients and malabsorption is common. The epithelium of the biliary tract and the pancreatic duct can be infected with Cryptosporidium
, leading to sclerosing cholangitis and to pancreatitis secondary to papillary stenosis, particularly among patients with prolonged disease and low CD4 cell counts.5-8
Pulmonary infections also have been reported,9,10
and may be under-recognized.11
Diagnosis of cryptosporidiosis can be made by microscopic identification of the oocysts in stool or tissue with acid-fast staining or direct immunofluorescence, which offers better sensitivity.12
Immunofluorescence is estimated to be 10 times more sensitive than acid-fast staining and is now the gold standard for stool examination. Concentration methods (i.e., formalin ether or formalin-ethyl acetate) and flotation methods (i.e., Sheather’s sucrose or sodium chloride) may facilitate diagnosis, but they are very labor intensive and not routinely used in clinical laboratories. Antigen-detection by enzyme-linked immunosorbent assay or immunochromatographic tests also are useful, with sensitivities reportedly ranging from 66% to 100%, depending on the specific test. Molecular methods such as polymerase chain reaction (PCR) are even more sensitive,13
detecting as few as five oocysts in spiked stool samples and nearly double the number of cases identified by microscopic methods. Cryptosporidial enteritis also can be diagnosed from small sections from intestinal biopsy.
A single stool specimen is usually adequate for diagnosis in individuals with profuse diarrheal illness, whereas repeat stool sampling is recommended for those with milder disease.
HIV-infected individuals should be educated and counseled about the different ways that Cryptosporidium
can be transmitted (BIII
). Modes of transmission include having direct contact with infected adults, diaper-aged children, and infected animals; coming into contact with contaminated water during recreational activities; drinking contaminated water; and eating contaminated food.
Detailed prevention recommendations related to food and water exposures (including methods for removing Cryptosporidium
from drinking water), pet exposures, and travel-related exposures can be found in Appendix A: Recommendations to Help HIV-infected Patients Avoid Exposure to, or Infection from, Opportunistic Pathogens
Scrupulous handwashing can reduce the risk of diarrhea in HIV-infected individuals, including diarrhea caused by Cryptosporidium
HIV-infected patients should be advised to wash their hands after potential contact with human feces (including after diapering small children). Hand-washing also should be recommended in association with the following activities: after handling pets or other animals, gardening or having other contact with soil; before preparing food or eating; and before and after sex (BIII
). HIV-infected patients should avoid unprotected sex, especially practices that could lead to direct (e.g., oral-anal) or indirect (e.g., penile-anal) contact with feces. They should be advised to use barriers such as condoms and dental dams during sex to reduce such exposures (BIII
HIV-infected individuals—particularly those with CD4 counts <200 cells/µL—should avoid direct contact with diarrhea or stool from pets (BIII
). Gloves should be worn when handling feces or cleaning areas that might have been contaminated by feces from pets (BIII
). They should also limit or avoid direct exposure to calves and lambs (BII
). Paying attention to hygiene and avoiding direct contact with stool are important when visiting premises such as farms or petting zoos where these animals are housed or exhibited.
HIV-infected individuals should not drink water directly from lakes or rivers (AIII)
. Waterborne infection also can result from swallowing water during recreational activities. HIV-infected individuals should be made aware that lakes, rivers, and salt water beaches and some swimming pools, recreational water parks, and ornamental water fountains may be contaminated with human or animal waste that contains Cryptosporidium
. They should avoid swimming in water that is likely contaminated and should avoid swallowing water while swimming or playing in recreational water (BIII
Outbreaks of cryptosporidiosis have been linked to drinking water from municipal water supplies. During outbreaks or in other situations that impose a community advisory to boil water, boiling water for at least 1 minute will eliminate the risk for cryptosporidiosis (AIII
). Using submicron personal-use water filters (home/office types) or bottled water also may reduce the risk of infection from municipal and well water (BII
For persons with low CD4 cell counts, the magnitude of the risk of acquiring cryptosporidiosis from drinking water in a non-outbreak setting is uncertain, and available data are inadequate to recommend that all HIV-infected persons boil water or avoid drinking tap water in non-outbreak settings. However, HIV-infected individuals should consider drinking only filtered water (CIII
), despite the complexities involved in selecting appropriate products, the lack of enforceable standards for removal of oocysts, the costs of the products, and the logistic difficulty of using these products consistently. Note that ice made from contaminated tap water also can be a source of infection.
HIV-infected patients with low CD4 cell counts should be cautious about eating raw oysters because cryptosporidial oocysts can survive in oysters for longer than 2 months and have been found in oysters taken from certain commercial oyster beds (CIII
). In the hospital setting, standard precautions for use of gloves and for hand-washing after removal of gloves should be sufficient to prevent transmission of cryptosporidiosis from an infected patient to a susceptible HIV-infected individual (BIII
). Because of the potential for fomite transmission, some specialists recommend that HIV-infected patients, especially individuals who are severely immunocompromised, not share a room with a patient with cryptosporidiosis (CIII
HIV-infected individuals who travel to developing countries should be warned to avoid drinking tap water or using tap water to brush their teeth (BIII
). Ice that is not made from bottled water and consumption of raw fruits or vegetables that could have been washed in tap water should also be avoided (BIII
). HIV-infected individuals also should avoid other sources of Cryptosporidium
oocysts as much as possible (BIII
). These include working directly with people with diarrhea; with farm animals such as cattle and sheep; and with domestic pets that are very young or have diarrhea. If exposure is unavoidable, gloves should be used and practices for good hand hygiene observed.
Because chronic cryptosporidiosis occurs primarily in patients with advanced immunodeficiency, appropriate initiation of combination ART before the patient becomes severely immunosuppressed should prevent this disease (AII
). Rifabutin and possibly clarithromycin, when taken for Mycobacterium avium
complex prophylaxis, have been found to protect against cryptosporidiosis.15,16
Data are insufficient, however, to warrant a recommendation for using rifabutin or clarithromycin as chemoprophylaxis for cryptosporidiosis.
In the setting of severe immune suppression, ART with immune restoration to a CD4 count >100 cells/µL usually leads to resolution of clinical cryptosporidiosis17-21
and is the mainstay of treatment. Therefore, patients with cryptosporidiosis should be started on ART as part of the initial management of their infection (AII
). HIV protease inhibitors (PIs) can inhibit Cryptosporidium in vitro
and in animal models, and some experts believe that PI-based ART is preferable in patients with documented cryptosporidiosis (CIII
Management should also include symptomatic treatment of diarrhea with anti-motility agents (AIII
). Tincture of opium may be more effective than loperamide (CIII
). Octreotide, a synthetic octapeptide analog of naturally occurring somatostatin that is approved to treat secreting tumor-induced diarrhea, is no more effective than other oral antidiarrheal agents and is usually not
Because diarrhea can cause lactose deficiency, patients should avoid milk products (CIII
Rehydration and repletion of electrolyte losses by either the oral or intravenous route are important. Severe diarrhea can exceed >10 L/day among patients with AIDS, often requiring intensive support. Oral rehydration should be pursued aggressively with oral rehydration solutions (AIII
Patients with biliary tract involvement may require endoscopic retrograde choledocoduodenoscopy for diagnosis. They may also benefit from sphincterotomy and/or stenting.25
Several agents have been investigated in small, randomized controlled clinical trials of HIV-infected adults, including nitazoxanide, paromomycin, spiramycin, bovine hyperimmune colostrum, and bovine dialyzable leukocyte extract. No pharmacologic or immunologic therapy directed specifically against Cryptosporidium
has been shown to be consistently effective when used without ART.19
Nitazoxanide is an orally administered nitrothiazole benzamide with in vivo
activity against a broad range of helminths, bacteria, and protozoa.26,27
It is approved by the U.S. Food and Drug Administration for treatment of cryptosporidiosis in children and adults. When administered for 3 days at 500 mg twice daily to HIV-uninfected adults with cryptosporidiosis, nitazoxanide resulted in higher rates of diarrhea resolution and oocyst-free stools than placebo.26
In one study, HIV-infected adults with cryptosporidiosis with CD4 counts >50 cells/µL were treated with nitazoxanide 500 to 1000 mg twice daily for 14 days; they experienced substantially higher rates of parasitological cure and resolution of diarrhea than those in the placebo group.27
This finding was not confirmed, however, in two randomized trials in children.28,29
Data from a compassionate use program before the advent of potent ART, which included primarily white male adults with median CD4 counts less than 50 cells/µL, reported that a majority of patients experienced some degree of clinical response (reduction in frequency of total stool and of liquid stools), usually within the first week of treatment.30
Adverse events associated with nitazoxanide are limited and typically mild, and no important drug-drug interactions have been reported. Because of the clinical significance of cryptosporidiosis, a trial of nitazoxanide or other anti-parasitic drugs in conjunction with ART, but never instead of ART, can be considered (CIII
Paromomycin is a non-absorbable aminoglycoside indicated for the treatment of intestinal amebiasis but not specifically approved for cryptosporidiosis. It is effective in high doses for the treatment of cryptosporidiosis in animal models.31
A meta-analysis of 11 published studies of paromomycin in humans reported a response rate of 67%; however, relapses were common, with long-term success rates of only 33%.25
Two randomized trials comparing paromomycin with placebo among patients with AIDS and cryptosporidiosis showed that the drug had limited effectiveness in patients with AIDS,32,33
and a meta-analysis of the two trials found the drug was not significantly more effective than placebo at reducing diarrheal frequency or parasite burden, but that analysis was limited by the small sample size and methodologic problems.19
One case series suggested a better response rate in patients receiving paromomycin along with ART.34
Paromomycin may be used instead of nitazoxanide along with, but never instead of ART (CIII
Special Considerations with Regard to Starting ART
As noted above, patients with cryptosporidiosis should be offered ART as part of the initial management of their infection (AII
). PIs can inhibit Cryptosporidium in vitro
and in animal models, thus some authorities feel that PI-based ART is preferable in patients with documented cryptosporidiosis (CIII
Monitoring of Response to Therapy and Adverse Events (including IRIS)
Patients should be monitored closely for signs and symptoms of volume depletion, electrolyte imbalance, weight loss, and malnutrition. Total parenteral nutrition may be indicated in certain patients (CIII
). Immune reconstitution inflammatory syndrome (IRIS) has not been described in association with treatment of cryptosporidiosis.
Managing Treatment Failure
Supportive treatment and optimization of ART to achieve full virologic suppression are the only feasible approaches to managing treatment failure (AIII
No pharmacologic interventions are known to be effective in preventing the recurrence of cryptosporidiosis.
Special Considerations During Pregnancy
Rehydration and initiation of ART are the mainstays of initial treatment of cryptosporidiosis during pregnancy, as they are in non-pregnant women (AII
). Pregnancy should not preclude the use of ART and in fact is always an indication for ART.35
Nitazoxanide is not teratogenic in animals but no human data on use in pregnancy are available. Nitazoxanide can be used in pregnancy after the first trimester in women with severe symptoms (CIII
). Limited information is available about the teratogenic potential of paromomycin, but oral administration is associated with minimal systemic absorption, which may minimize potential risk. Paromomycin can be used in pregnancy after the first trimester in women with severe symptoms (CIII
). Loperamide is poorly absorbed and has not been associated with birth defects in animal studies. However, a recent study identified an increased risk of congenital malformations, and specifically hypospadias, among 683 women with exposure to loperamide early in pregnancy.36
Therefore, loperamide should be avoided in the first trimester, unless benefits are felt to outweigh potential risks (CIII
). Loperamide is the preferred anti-motility agent in late pregnancy (CIII
). Opiate exposure in late pregnancy has been associated with neonatal respiratory depression, and chronic exposure may result in neonatal withdrawal, therefore tincture of opium is not
recommended in late pregnancy (AIII
Recommendations for Preventing and Managing Cryptosporidiosis
| Preventing Chronic Cryptosporidiosis
- Because chronic cryptosporidiosis occurs primarily in persons with advanced immunodeficiency, initiation of ART before the patient becomes severely immunosuppressed should prevent the disease (AII).
Preferred Management Strategies:
Alternative Management Strategies:
- Initiate or optimize ART for immune restoration to CD4 count >100 cells/mm3 (AII).
- Aggressive oral and/or IV rehydration and replacement of electrolyte loss (AIII), and symptomatic treatment of diarrhea with anti-motility agent (AIII).
- Tincture of opium may be more effective than loperamide (CIII).
No therapy has been shown to be effective without ART. Trial of these agents may be used in conjunction with, but not instead of, ART:
- Nitazoxanide 500–1000 mg PO BID with food for 14 days (CIII) + optimized ART, symptomatic treatment, and rehydration and electrolyte replacement, or alternatively
- Paromomycin 500 mg PO QID for 14 to 21 days (CIII) + optimized ART, symptomatic treatment and rehydration and electrolyte replacement
- Since diarrhea can cause lactose deficiency, patients should avoid milk products (CIII).
Flanigan T, Whalen C, Turner J, et al. Cryptosporidium infection and CD4 counts. Ann Intern Med. May 15 1992;116(10):840-842. Available at http://www.ncbi.nlm.nih.gov/pubmed/1348918.
Cama V, Gilman RH, Vivar A, et al. Mixed Cryptosporidium infections and HIV. Emerg Infect Dis. Jun 2006;12(6):1025-1028. Available at http://www.ncbi.nlm.nih.gov/pubmed/16707069.
Tumwine JK, Kekitiinwa A, Bakeera-Kitaka S, et al. Cryptosporidiosis and microsporidiosis in Ugandan children with persistent diarrhea with and without concurrent infection with the human immunodeficiency virus. Am J Trop Med Hyg. Nov 2005;73(5):921-925. Available at http://www.ncbi.nlm.nih.gov/pubmed/16282304.
Buchacz K, Baker RK, Palella FJ, Jr., et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS. Jun 19 2010;24(10):1549-1559. Available at http://www.ncbi.nlm.nih.gov/pubmed/20502317.
Ducreux M, Buffet C, Lamy P, et al. Diagnosis and prognosis of AIDS-related cholangitis. AIDS. Aug 1995;9(8):875-880. Available at http://www.ncbi.nlm.nih.gov/pubmed/7576321.
Chen XM, LaRusso NF. Cryptosporidiosis and the pathogenesis of AIDS-cholangiopathy. Semin Liver Dis. Aug 2002;22(3):277-289. Available at http://www.ncbi.nlm.nih.gov/pubmed/12360421.
Chen C, Gulati P, French SW. Pathologic quiz case: a patient with acquired immunodeficiency syndrome and an unusual biliary infection. Arch Pathol Lab Med. Feb 2003;127(2):243-244. Available at http://www.ncbi.nlm.nih.gov/pubmed/12562247.
de Souza Ldo R, Rodrigues MA, Morceli J, Kemp R, Mendes RP. Cryptosporidiosis of the biliary tract mimicking pancreatic cancer in an AIDS patient. Rev Soc Bras Med Trop. Mar-Apr 2004;37(2):182-185. Available at http://www.ncbi.nlm.nih.gov/pubmed/15094908.
Moore JA, Frenkel JK. Respiratory and enteric cryptosporidiosis in humans. Arch Pathol Lab Med. Nov 1991;115(11):1160-1162. Available at http://www.ncbi.nlm.nih.gov/pubmed/1747035.
Mercado R, Buck GA, Manque PA, Ozaki LS. Cryptosporidium hominis infection of the human respiratory tract. Emerg Infect Dis. Mar 2007;13(3):462-464. Available at http://www.ncbi.nlm.nih.gov/pubmed/17552101.
Mor SM, Tumwine JK, Ndeezi G, et al. Respiratory cryptosporidiosis in HIV-seronegative children in Uganda: potential for respiratory transmission. Clin Infect Dis. May 15 2010;50(10):1366-1372. Available at http://www.ncbi.nlm.nih.gov/pubmed/20377408.
Weber R, Bryan RT, Bishop HS, Wahlquist SP, Sullivan JJ, Juranek DD. Threshold of detection of Cryptosporidium oocysts in human stool specimens: evidence for low sensitivity of current diagnostic methods. J Clin Microbiol. Jul 1991;29(7):1323-1327. Available at http://www.ncbi.nlm.nih.gov/pubmed/1715881.
Nair P, Mohamed JA, DuPont HL, et al. Epidemiology of cryptosporidiosis in North American travelers to Mexico. Am J Trop Med Hyg. Aug 2008;79(2):210-214. Available at http://www.ncbi.nlm.nih.gov/pubmed/18689626.
Huang DB, Zhou J. Effect of intensive handwashing in the prevention of diarrhoeal illness among patients with AIDS: a randomized controlled study. J Med Microbiol. May 2007;56(Pt 5):659-663. Available at http://www.ncbi.nlm.nih.gov/pubmed/17446290.
Holmberg SD, Moorman AC, Von Bargen JC, et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. JAMA. Feb 4 1998;279(5):384-386. Available at http://www.ncbi.nlm.nih.gov/pubmed/9459473.
Fichtenbaum CJ, Zackin R, Feinberg J, Benson C, Griffiths JK, Team ACTGNWCS. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. AIDS. Dec 22 2000;14(18):2889-2893. Available at http://www.ncbi.nlm.nih.gov/pubmed/11153670.
Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet. Jan 24 1998;351(9098):256-261. Available at http://www.ncbi.nlm.nih.gov/pubmed/9457096.
Miao YM, Awad-El-Kariem FM, Franzen C, et al. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J Acquir Immune Defic Syndr. Oct 1 2000;25(2):124-129. Available at http://www.ncbi.nlm.nih.gov/pubmed/11103042.
Cabada MM, White AC, Jr. Treatment of cryptosporidiosis: do we know what we think we know? Curr Opin Infect Dis. Oct 2010;23(5):494-499. Available at http://www.ncbi.nlm.nih.gov/pubmed/20689422.
Dillingham RA, Pinkerton R, Leger P, et al. High early mortality in patients with chronic acquired immunodeficiency syndrome diarrhea initiating antiretroviral therapy in Haiti: a case-control study. Am J Trop Med Hyg. Jun 2009;80(6):1060-1064. Available at http://www.ncbi.nlm.nih.gov/pubmed/19478276.
Maggi P, Larocca AM, Quarto M, et al. Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis. Mar 2000;19(3):213-217. Available at http://www.ncbi.nlm.nih.gov/pubmed/10795595.
Mele R, Gomez Morales MA, Tosini F, Pozio E. Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. Int J Parasitol. Jul 2003;33(7):757-764. Available at http://www.ncbi.nlm.nih.gov/pubmed/12814654.
Hommer V, Eichholz J, Petry F. Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum. J Antimicrob Chemother. Sep 2003;52(3):359-364. Available at http://www.ncbi.nlm.nih.gov/pubmed/12888587.
Simon DM, Cello JP, Valenzuela J, et al. Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. Gastroenterology. Jun 1995;108(6):1753-1760. Available at http://www.ncbi.nlm.nih.gov/pubmed/7768380.
]Hashmey R, Smith NH, Cron S, Graviss EA, Chappell CL, White AC, Jr. Cryptosporidiosis in Houston, Texas. A report of 95 cases. Medicine (Baltimore). Mar 1997;76(2):118-139. Available at http://www.ncbi.nlm.nih.gov/pubmed/9100739.
Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. J Infect Dis. Jul 1 2001;184(1):103-106. Available at http://www.ncbi.nlm.nih.gov/pubmed/11398117.
Rossignol JF, Hidalgo H, Feregrino M, et al. A double-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg. Nov-Dec 1998;92(6):663-666. Available at http://www.ncbi.nlm.nih.gov/pubmed/10326116.
Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet. Nov 2 2002;360(9343):1375-1380. Available at http://www.ncbi.nlm.nih.gov/pubmed/12423984.
Amadi B, Mwiya M, Sianongo S, et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect Dis. 2009;9:195. Available at http://www.ncbi.nlm.nih.gov/pubmed/19954529.
Rossignol JF. Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients. Aliment Pharmacol Ther. Sep 1 2006;24(5):887-894. Available at http://www.ncbi.nlm.nih.gov/pubmed/16918894.
Tzipori S, Rand W, Griffiths J, Widmer G, Crabb J. Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin. Clin Diagn Lab Immunol. Jul 1994;1(4):450-463. Available at http://www.ncbi.nlm.nih.gov/pubmed/8556484.
White AC, Jr., Chappell CL, Hayat CS, Kimball KT, Flanigan TP, Goodgame RW. Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J Infect Dis. Aug 1994;170(2):419-424. Available at http://www.ncbi.nlm.nih.gov/pubmed/8035029.
Hewitt RG, Yiannoutsos CT, Higgs ES, et al. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin Infect Dis. Oct 2000;31(4):1084-1092. Available at http://www.ncbi.nlm.nih.gov/pubmed/11049793.
Maggi P, Larocca AM, Ladisa N, et al. Opportunistic parasitic infections of the intestinal tract in the era of highly active antiretroviral therapy: is the CD4(+) count so important? Clin Infect Dis. Nov 1 2001;33(9):1609-1611. Available at http://www.ncbi.nlm.nih.gov/pubmed/11588705.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at /contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed on March 4, 2013.
Kallen B, Nilsson E, Otterblad Olausson P. Maternal use of loperamide in early pregnancy and delivery outcome. Acta Paediatr. May 2008;97(5):541-545. Available at http://www.ncbi.nlm.nih.gov/pubmed/18394096.